| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | GD2 |
| Clinical data | |
| Routes of administration | intravenous |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
3F8 is a murine IgG31 monoclonal antibody which binds to GD2.2
It has been used in the detection and treatment of neuroblastoma.3 For imaging neuroblastoma, it is labelled with one of the radioisotopes iodine-124 and iodine-131.45
References
References
- Kushner BH, Cheung NK (May 1989). "GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma". Blood. 73 (7): 1936–41. doi:10.1182/blood.V73.7.1936.1936. PMID 2653466.
- "Sloan-Kettering - Neuroblastoma: 3F8 Monoclonal Antibody Therapy Q & A". Retrieved 2008-02-19.
- Weinstein JL, Katzenstein HM, Cohn SL (1 June 2003). "Advances in the diagnosis and treatment of neuroblastoma". The Oncologist. 8 (3): 278–92. doi:10.1634/theoncologist.8-3-278. PMID 12773750. S2CID 20705441.
- Yeh SD, Larson SM, Burch L, Kushner BH, Laquaglia M, Finn R, Cheung NK (May 1991). "Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities". Journal of Nuclear Medicine. 32 (5): 769–76. PMID 1902508.
- Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C (January 2007). "Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". Health Physics. 92 (1): 33–9. doi:10.1097/01.HP.0000231583.32904.6c. PMID 17164597. S2CID 25792466.